Aim To determine the expression pattern and prognostic value of heparan sulfate in gastric cancer.
Method The 10E4 antiheparan sulfate monoclonal antibody was used to examine the expression pattern of heparan sulfate in tissue microarrays consisting of 162 cases of gastric carcinoma by immunohistochemistry. The immunoreactivities of both epithelial and stromal components of the specimens were examined and analysed statistically for significant associations with clinicopathological parameters, including histological grade of the tumour, extent of cancer infiltration and presence of lymph-node metastases, lymphovascular invasion, perineural invasion, perforation of gastric wall and stromal reaction. The potential use of heparan sulfate as a predictive factor for patient survival was also evaluated.
Results Reduced expression of heparan sulfate in the epithelial component was associated with higher histological grades of gastric cancer as well as the presence of more extensive tumour infiltration. Furthermore, this decrease in heparan sulfate expression was found to be predictive of reduced patient survival after tumour recurrence.
Conclusion The data suggest that heparan sulfate may play an important role in regulating the biology of gastric cancer, and that it may be a useful prognostic marker of this tumour.
- Heparan sulfate
- gastric carcinoma
- prognostic marker
- tissue microarray
- gastric cancer
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding The project was supported by Singapore Gastric Cancer Consortium Grant NMRC/TCR/001/NUS/2007 and Singapore Cancer Syndicate Grant SCS MS4R. S-LL is the recipient of a graduate research scholarship from the National University of Singapore.
Competing interests None.
Ethics approval Ethics approval was provided by the Institutional Review Board, Singapore General Hospital.
Provenance and peer review Not commissioned; not externally peer reviewed.